Nolasiban
chemical compound
Nolasiban (INNTooltip International Nonproprietary Name; developmental code names OBE001 and RPN-002), also known previously as erlosiban, is an oxytocin receptor antagonist which is under development for the treatment of female infertility and adenomyosis. It was also under development for the treatment of preterm labor, but development for this indication was discontinued. The drug is a small molecule or non-peptide and is taken orally.
The drug interacts with both the oxytocin receptor (Ki = 52 nM; IC50Tooltip half-maximal inhibitory concentration = 81 nM) and the vasopressin V1A receptor (Ki = 120 nM), whereas findings for the vasopressin V2 receptor were not reported. It is of relatively low potency, being used and studied clinically at doses of 900 to 2,400 mg orally.
Nolasiban was first described in the scientific literature by 2015. It was originated by Merck Serono and is under development by ObsEva and ReproNovo. As of July 2026, the drug is in phase 2 clinical trials for female infertility and phase 1 trials for adenomyosis. It was also previously in phase 3 trials in the late 2010s.
The public source identifies “Nolasiban” as chemical compound. This brief keeps that definition visible, then builds a research path around Nolasiban, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Nolasiban”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 20, 2026. The linked authority identifier is Q27256636. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2015 and 2026.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Nolasiban”, its source revision and the description used here.
- Expand the search: follow Nolasiban primary sources, Nolasiban archive and Nolasiban research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Nolasiban”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Nolasiban” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.